Staphylococcus intermedius Infection Models

Staphylococcus intermedius (S. intermedius) is a Gram-positive, coagulase-positive staphylococcus originally isolated from the nostrils of pigeons, dogs, and horses. It is a member of the Staphylococcus intermedius group (SIG), which also contains Staphylococcus pseudintermedius and Staphylococcus delphini. It is an animal-associated organism that is also zoonotic, causing bacteremia, pneumonia, and skin and wound infections in humans who are in close contact with animals, most often dogs.

It is not an ESKAPE pathogen and is not listed on the WHO Bacterial Priority Pathogens List; its development case is in companion-animal health and in zoonotic human infection. TransPharm Preclinical Solutions can develop and validate a custom SIG infection model to a program’s specifications.

The scientific problem in an S. intermedius program begins with identity. The SIG is defined by a group of closely related, coagulase-positive, animal-adapted staphylococci that are difficult to tell apart by standard biochemical methods. Because the clinically dominant member is S. pseudintermedius – the leading cause of canine pyoderma and otitis and a common colonizer of dogs – a program nominally aimed at S. intermedius is very often, in practice, aimed at S. pseudintermedius. Confirming which species is in hand is therefore the first design decision.

The second is resistance. Methicillin-resistant S. pseudintermedius (MRSP), which carries the mecA-encoded resistance that defines methicillin resistance in staphylococci and is frequently multidrug-resistant, has emerged as a major problem in companion-animal medicine and is a recognized zoonotic concern. A resistant isolate is a relevant challenge for programs positioned against resistant disease.

For the human and mammalian disease, the group’s presentations – skin and soft-tissue infection, bacteremia, and pneumonia – map onto the infection models that TransPharm Preclinical Solutions runs for other staphylococci. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized SIG isolates, including defined species and resistant phenotypes, to a program’s specifications.

S. intermedius is validated on request. For its human and mammalian disease, its principal presentations align with the established rodent platform – a soft-tissue model for skin and wound infection, a bacteremia model for systemic disease, and a pulmonary model for pneumonia. Any of these can be developed and validated, with the species confirmed and the challenge strain, host species and strain, route of administration, comparators, dosing, and endpoints configured to the program.

Core readouts are quantitative bacterial burden (CFU) in target tissues, organs, and blood, with survival and mortality tracking where applicable, and pharmacokinetic profiling, blood chemistry, additional tissue harvests, and histopathology available as add-ons. Contact TransPharm Preclinical Solutions to scope a study design suited to your candidate.

Resistance in the S. intermedius group is, in practice, the story of methicillin-resistant S. pseudintermedius. Like methicillin-resistant S. aureus, MRSP carries the mecA gene encoding an altered penicillin-binding protein that renders the β-lactam class largely ineffective. As MRSP isolates are commonly multidrug-resistant, this leaves few available options in companion-animal practice; distinct clonal lineages predominate in Europe and North America, and carriage by pets, owners, and veterinary staff underlies its zoonotic potential. Because the resistances that matter are concentrated in S. pseudintermedius and because SIG members are readily misidentified, accurate species identification is essential to interpreting susceptibility and to designing a study that speaks to the intended organism.